Although there are currently no biomarkers with proven clinical interest to identify patients eligible to bevacizumab and chemotherapy, a pilot study performed on 34 metastatic colorectal cancer patients treated with chemotherapy and bevacizumab showed that high levels of plasma angiopoietin-2 predict a poor prognosis[14]. This evidence concerns the gene ANGPT2 and metastatic colorectal cancer.